Skip to content
Screener

Cash & Equivalents at other companies

Baxter International logo
Baxter InternationalBAX
$2.02B-12.1%
Revvity logo
RevvityRVTY
$861.47M-24.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Utah Medical Products logo
Utah Medical ProductsUTMD
$87.53M+6.5%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Medtronic logo
MedtronicMDT
$1.95B-12.1%

Other financials

Income statement

See full
Revenue$1.1B+7.9%
Gross profit$735.4M+8.3%
Operating income-$31.0M-117%
Net income-$77.9M-189%
EPS (diluted)-$0.40-191%

Balance sheet

See full
Total debt$3.1B+15.6%
Total equity$8.2B-0.6%
Total assets$12.5B+0.6%

Cash flow

See full
Operating cash flow$182.8M+90.0%
CapEx$86.4M+10.6%
Free cash flow$96.4M+433%

Valuation

See full
Market cap$14.57B+7.4%
Enterprise value$17.49B+9.5%
P/E61.8×+28.5×
P/S3.4×+0.1×

Profitability

See full
Gross margin65.5%-1.6pp
Operating margin11.8%-7.2pp
Net margin5.6%-4.8pp
FCF margin13.5%+4.3pp

Returns & leverage

See full
Return on equity2.9%-2.3pp
Debt / equity0.4×+0.1×
Current ratio1.3×-0.8×

Where this comes from

Reported directly by The Cooper Companies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: The Cooper Companies, Inc.’s 10-Q, filed June 5, 2026.

Filed
Jun 5, 2026, 4:47 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-041305
Line item20262025
Effect of exchange rate changes on cash, cash equivalents and restricted cash1.32.9
Net increase in cash, cash equivalents, and restricted cash28.48.5
Cash, cash equivalents, and restricted cash at beginning of period110.6107.7
Cash, cash equivalents, and restricted cash at end of period$139.0$116.2
Reconciliation of cash flow information:
Cash and cash equivalents$138.8$116.2
Restricted cash included in other current assets0.2
Total cash, cash equivalents, and restricted cash$139.0$116.2

Item 1. Unaudited Financial Statements

FAQ

What is The Cooper Companies, Inc.'s cash & equivalents?
The Cooper Companies, Inc. (COO) reported cash & equivalents of $139M in Q1 2026.
How has The Cooper Companies, Inc.'s cash & equivalents changed year-over-year?
The Cooper Companies, Inc.'s cash & equivalents increased by 19.6% year-over-year, from $116.2M to $139M.
What is the long-term trend for The Cooper Companies, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), The Cooper Companies, Inc.'s cash & equivalents has grown at a -1.1% compound annual growth rate (CAGR), from $116.8M to $110.6M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about The Cooper Companies, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude